newsfilter
← Latest News
GlobeNewswire·

Alpha Tau to Host Investor Call to Review New Data from the Alpha DaRT® Recurrent Glioblastoma REGAIN Trial

  • Alpha Tau Medical Ltd. will host a conference call & webcast on Monday, Nov. 16, 2026, at 8:30 a.m. ET to discuss interim REGAIN trial results.
  • The REGAIN trial is a U.S. multicenter study evaluating Alpha DaRT for recurrent glioblastoma patients ineligible for surgical resection.
  • Results will be presented at the 31st Annual Meeting of the Society for Neuro-Oncology in Philadelphia from Nov. 12-15, 2026.
  • Call speakers include Principal Investigator Dr. Joshua Palmer, CEO Uzi Sofer, CMO Robert Den, MD, & CFO Raphi Levy.
  • The REGAIN study aims to enroll up to 20 patients who have undergone prior central nervous system radiation.
  • Alpha DaRT utilizes radium-224 sources to deliver alpha particles that destroy tumors while sparing healthy tissue.
  • The technology has received marketing approval in Japan for head & neck cancer & in Israel for skin & oral cavity squamous cell carcinoma.
  • Alpha Tau has not received commercialization approval for Alpha DaRT in glioblastoma patients outside of clinical trials.
  • Forward-looking statements include risks regarding regulatory approvals, funding needs, patient enrollment, & potential side effects.
  • An archived webcast will be available on the company website following the event.
Company
Alpha Tau Medical Ltd.
Keywords
Nasdaq:DRTS , Alpha Tau Medical Ltd., DRTS, REGAIN, Alpha DaRT, Alpha Tau Medical, Intratumoral, Glioblastoma, Recurrent glioblastoma, Brain Cancer, Radium224